<DOC>
	<DOCNO>NCT02914886</DOCNO>
	<brief_summary>The purpose study investigate whether zinc-free insulin effective treatment option lipoatrophy patient type 1 Diabetes ( T1D ) insulin pump ( CSII , continuous subcutaneous insulin infusion ) therapy .</brief_summary>
	<brief_title>Beneficial Effect Insulin Glulisine Lipoatrophy Type 1 Diabetes ( LAS )</brief_title>
	<detailed_description>Randomized , control , open-label parallel study . Clinical Study Phase IV After include study , subject get extensive dermatological examination pediatric dermatologist familiar cutaneous complication T1D , additionally pathological result document photography , necessary , videodermoscopy . Additionally , evaluation lipoatrophic area use image method like ultrasound ( USG ) MRI perform . After randomization , half include child switch pump insulin insulin glulisine ( intervention group ) 6 month . The others continue current treatment ( control group ) switch insulin glulisine 6 month later . Both group followed-up month 12 . Hence , 4th visit 6 month , enrol patient insulin glulisine pump period 6 month .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Patients type 1 diabetes document lipoatrophy injection sit CSII treatment Age 6 40 year ( inclusive , see rationale inclusion minor ) Signed informed consent form patient parents/their guardian children/youths &lt; 18 year Patients must willing undergo study procedures Patients previous use insulin glulisine Patients require corticosteroid treatment medication . NOTE inhale corticosteroid allow . Patients suffer severe chronic disease T1D genetic disorder ( i.e . Down syndrome etc . ) Pregnant lactate woman Patients participate device drug study History drug alcohol abuse within last five year prior screen Anamnestic history hypersensitivity study drug ( component study drug ) drug similar chemical structure History severe multiple allergy Treatment investigational drug within 3 month prior screen Progressive fatal disease History significant cardiovascular ( myocardial infarction , stroke , TIA ) , respiratory , gastrointestinal , hepatic ( ALT and/or AST &gt; 3 time normal reference range ) , renal ( creatinine &gt; 1.1 mg/dl woman &gt; 1.5 mg/dl men ) , neurological , psychiatric and/or hematological disease judge investigator Sexually active woman childbearing potential consistently correctly practice birth control implant , injectables , combine oral contraceptive , hormonal intrauterine device ( IUDs ) , sexual abstinence vasectomize partner Lack compliance similar reason , accord investigator , preclude satisfactory participation study Prisoners subject involuntarily incarcerate Target Disease Exclusions History T2DM , maturity onset diabetes young ( MODY ) , pancreatic surgery chronic pancreatitis Any use oral hypoglycemic agent within 12 month prior screen visit History diabetes ketoacidosis ( DKA ) within 12 week prior screen visit History hospital admission glycemic control ( either hyperglycemia hypoglycemia ) within 3 month prior screen visit Frequent episodes hypoglycemia define one episode require assistance , emergency care ( paramedic emergency room care ) glucagon therapy , 2 unexplained episode symptomatic hypoglycemia within 3 month prior screen visit . An unexplained event define event explain circumstance dietary ( e.g . miss meal ) , strenuous exercise , error insulin dosing , etc . Hypoglycemic unawareness History diabetes insipidus History Addison 's disease chronic adrenal insufficiency Physical Laboratory Test Findings BMI 35 kg/m2 RR &gt; 180/110 mm Hg Aspartate aminotransferase ( AST ) &gt; 3X Upper limit normal ( ULN ) Alanine aminotransferase ( ALT ) &gt; 3X ULN Serum total bilirubin &gt; 3X ULN Estimated GFR ( eGFR ) &lt; 60 ml/min/1.73 m2 Hemoglobin ≤ 11.0 g/dl ( 110 g/l ) boys / men ; hemoglobin ≤10.0 g/dl ( 100 g/L ) girl / woman . Creatine kinase ( CK ) &gt; 3X ULN Positive hepatitis B surface antigen antihepatitis C virus antibody . Abnormal Free T4 Note : abnormal TSH value screen evaluate free T4 . Subjects abnormal free T4 value exclude . A onetime retest may allow , determine Investigator , minimum 6 week follow adjustment thyroid hormone replacement therapy subject prior diagnosis thyroid disorder currently receive thyroid replacement therapy . Such case discuss Investigator prior retesting .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Lipoatrophy</keyword>
	<keyword>child</keyword>
	<keyword>adolescent</keyword>
	<keyword>adult</keyword>
	<keyword>insulin therapy</keyword>
</DOC>